Amplo Biotechnology
Amplo Biotechnology is to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Amplo Biotechnology Information
Geographic Data
Address: -
City: New York City
State: NY
Zip: 10001
Country: US
Financial Info
Stage:
grant
Raised Last:
$0
Raised Total:$2M
Social
Metrics
3,960,453Website Global Rank
2,800Website Monthly Traffic
Twitter Followers
Description
Diseases of the neuromuscular junction have profound health effects including paralysis, breathing and swallowing difficulties. Amplo Biotechnology plans to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction with an initial focus on congenital myasthenic syndromes. Amplo’s lead program, AAV-Dok7, was developed by Professor Yuji Yamanashi&s;s group of the Institute of Medical Science at the University of Tokyo, and is applicable to multiple rare, severe diseases.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 10/2021 | Seed Round | $2.2M | 10/2021 | Grant | 1 | - |
National Institutes of Health (NIH) National Institutes of Health (NIH) |
10/2021 | Seed | - | 10/2021 | Seed | - |
BioBrit, LLC Casdin Capital SeedFolio BioBrit, LLC Casdin Capital SeedFolio |
10/2021 | Grant | 1 | - |
National Institutes of Health (NIH) National Institutes of Health (NIH) |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
